IP Library Granted Patent US 7,201,920
Granted Patent B2
US 7,201,920 · App. 10/723,654 · Granted Apr 10, 2007

Methods and compositions for deterring abuse of opioid containing dosage forms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,201,920
App. No.
10/723,654
Granted
Apr 10, 2007
Kind
B2
Abstract

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Claims (70)

1. A therapeutic pharmaceutical composition comprising

a mixture including

(a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, β-hydroxy-3-methylfentanyl, levo-α-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, prepoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt thereof;

(b) gel forming polyethylene oxide at about 3 to 40% by weight;

(c) at least one disintegrant at about 2 to 25% by weight, selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and

(d) a nasal tissue irritant, wherein the composition functions such that less than about 50% of the total amount of opioid analgesic in the composition is recovered when about 490 mg. of the composition is contacted with 15 ml of water.

2. The therapeutic pharmaceutical composition of claim 1 , further comprising an emetic.

3. The therapeutic pharmaceutical composition of claim 1 , wherein the gel forming polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.

4. The therapeutic pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in unit dose form.

5. The therapeutic pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

6. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.

7. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

8. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

9. The therapeutic pharmaceutical composition of claim 8 , wherein the disintegrant is crospovidone.

10. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is morphine or a pharmaceutically acceptable salt thereof.

11. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is codeine or a pharmaceutically acceptable salt thereof.

12. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is hydromorphone or a pharmaceutically acceptable salt thereof.

13. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is propoxyphene or a pharmaceutically acceptable salt thereof.

14. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is tramadol or a pharmaceutically acceptable salt thereof.

15. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic comprises meperidine or a pharmaceutically acceptable salt thereof.

16. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is methadone or a pharmaceutically acceptable salt thereof.

17. The therapeutic pharmaceutical composition of claim 1 , wherein the analgesic is pentazocine or a pharmaceutically acceptable salt thereof.

18. The therapeutic pharmaceutical composition of claim 1 , wherein the disintegrant is crospovidone.

19. A therapeutic pharmaceutical composition comprising

a mixture including

(a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, β-hydroxy-3-methylfentanyl, levo-α-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt, thereof;

(b) gel forming polyethylene oxide at about 3 to 40% by weight;

(c) a surfactant at about 1 to 10% by weight;

(d) at least one disintegrant at about 2 to 25% by weight, wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and

(e) wherein the composition functions such that less than about 50% of the total amount of opioid analgesic in the composition is recovered when about 490 mg. of the composition is contacted with 15 ml of water.

20. The therapeutic pharmaceutical composition of claim 19 , further comprising an emetic.

21. The therapeutic pharmaceutical composition of claim 19 , wherein the gel forming polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.

22. The therapeutic pharmaceutical composition of claim 19 , wherein the pharmaceutical composition is in unit dose form.

23. The therapeutic pharmaceutical composition of claim 19 , wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

24. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.

25. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

26. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

27. The therapeutic pharmaceutical composition of claim 26 , wherein the disintegrant is crospovidone.

28. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is morphine or a pharmaceutically acceptable salt thereof.

29. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is codeine or a pharmaceutically acceptable salt thereof.

30. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is hydromophone or a pharmaceutically acceptable salt thereof.

31. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is propoxyphene or a pharmaceutically acceptable salt thereof.

32. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is tramadol or a pharmaceutically acceptable salt thereof.

33. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is meperidine or a pharmaceutically acceptable salt thereof.

34. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is methadone or a pharmaceutically acceptable salt thereof.

35. The therapeutic pharmaceutical composition of claim 19 , wherein the analgesic is pentazocine or a pharmaceutically acceptable salt thereof.

36. The therapeutic pharmaceutical composition of claim 19 , wherein the disintegrant is crospovidone.

37. A therapeutic pharmaceutical composition comprising:

a mixture including

(a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, β-hydroxy-3-methylfentanyl, levo-α-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt thereof;

(b) gel forming polyethylene oxide at about 3 to about 40 percent by weight;

(c) at least one disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and

(d) sodium lauryl sulfate at about 1 to 10 percent by weight.

38. The therapeutic pharmaceutical composition of claim 37 , further comprising an emetic.

39. The therapeutic pharmaceutical composition of claim 37 , wherein the gel forming polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.

40. The therapeutic pharmaceutical composition of claim 37 , wherein the pharmaceutical composition is in unit dose form.

41. The therapeutic pharmaceutical composition of claim 37 , wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

42. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.

43. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

44. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

45. The therapeutic pharmaceutical composition of claim 44 , wherein the disintegrant is crospovidone.

46. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is morphine or a pharmaceutically acceptable salt thereof.

47. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is codeine or a pharmaceutically acceptable salt thereof.

48. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is hydromorphone or a pharmaceutically acceptable salt thereof.

49. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is propoxyphene or a pharmaceutically acceptable salt thereof.

50. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is tramadol or a pharmaceutically acceptable salt thereof.

51. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is meperidine or a pharmaceutically acceptable salt thereof.

52. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is methadone or a pharmaceutically acceptable salt thereof.

53. The therapeutic pharmaceutical composition of claim 37 , wherein the analgesic is pentazocine or a pharmaceutically acceptable salt thereof.

54. The therapeutic pharmaceutical composition of claim 37 , wherein the disintegrant is crospovidone.

Assignments (14)
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY #14338143 PREVIOUSLY RECORDED ON REEL 033561 FRAME 0296. ASSIGNOR(S) HEREBY CONFIRMS THE LICENSE. Recorded Feb 25, 2016
From: ACURA PHARMACEUTICALS, INC
To: HIGHLAND PHARMACEUTICALS, LLC AND ITS AFFILIATES
Reel/Frame 038315/0279 →
LICENSE Recorded Aug 19, 2014
From: ACURA PHARMACEUTICALS, INC.; HIGHLAND PHARMACEUTICALS, LLC
To: HIGHLAND PHARMACEUTICALS, LLC
Reel/Frame 033561/0296 →
CHANGE OF NAME Recorded Jun 2, 2011
From: HALSEY DRUG CO., INC.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 026382/0156 →
RELEASE OF SECURITY INTEREST Recorded Oct 10, 2007
From: GALEN PARTNERS III, L.P.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 019930/0568 →
SECURITY AGREEMENT Recorded Jan 31, 2006
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 017097/0150 →
SECURITY AGREEMENT Recorded Nov 11, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016769/0109 →
SECURITY INTEREST Recorded Sep 19, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016814/0160 →
SECURITY INTEREST Recorded Jun 22, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016408/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2004
From: KUMAR, VIJAI; DIXON, DAVID; TEWARI, DIVYA; WADGAONKAR, DILIP B.
To: HALSEY DRUG COMPANY, INC.
Reel/Frame 014482/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2003
From: KUMAR, VIJAI; DIXON, DAVID; TEWARI, DIVYA; WADGAONKAR, DILIP B.
To: HALSEY DRUG COMPANY, INC.
Reel/Frame 014792/0068 →